Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Equity Average: 2011-2024

Historic Equity Average for Sunshine Biopharma (SBFM) over the last 10 years, with Dec 2024 value amounting to $22.4 million.

  • Sunshine Biopharma's Equity Average rose 2.79% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of $22.4 million for FY2024, which is 4.37% up from last year.
  • Per Sunshine Biopharma's latest filing, its Equity Average stood at $22.4 million for FY2024, which was up 4.37% from $21.4 million recorded in FY2023.
  • Sunshine Biopharma's 5-year Equity Average high stood at $22.4 million for FY2024, and its period low was -$845,111 during FY2020.
  • Moreover, its 3-year median value for Equity Average was $21.4 million (2023), whereas its average is $18.2 million.
  • In the last 5 years, Sunshine Biopharma's Equity Average crashed by 113.64% in 2020 and then skyrocketed by 3,038.64% in 2022.
  • Yearly analysis of 5 years shows Sunshine Biopharma's Equity Average stood at -$845,111 in 2020, then soared by 56.03% to -$371,588 in 2021, then soared by 3,038.64% to $10.9 million in 2022, then soared by 96.14% to $21.4 million in 2023, then rose by 4.37% to $22.4 million in 2024.